Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)

Bronchial Cancer Clinical Trial

— Stereotactic  

Official title:

Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05605236
• Other study ID #: 7460
• Status: Completed
• Start date: February 16, 2020
• Est. completion date: July 16, 2022

Study information

• Verified date: December 2023
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Bronchopulmonary cancer is the first cause of mortality in the world. We want to update the margins used in stereotactic radiotherapy, in the context of localized lung cancer, of non-surgical management. The investigators wish to redefine the stereotactic radiotherapy margins according to the histological type in localized non-small cell lung cancer. Indeed, these criteria were previously defined on a smaller cohort, in the context of 3D radiotherapy (mainly T3, T4 tumors). In addition, the incidence of radiation pneumonitis is highly dependent on the irradiated lung volume, which in turn depends on the CTV margins used.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: July 16, 2022
• Est. primary completion date: May 16, 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Major subject (=18 years old)
• Subject operated on at HUS for T1/T2a N0 stage lung adenocarcinoma or squamous cell carcinoma before 30/09/2019
• CT scan available on the HUS imaging server or on CD
• Subject who has not expressed opposition to the use of his or her data for research purposes

Exclusion Criteria:

• Subject who has expressed opposition to participating in the study
• Impossibility to give the subject informed information (difficulties in understanding the subject, ...)
• Subject under legal protection
• Subject under guardianship or curatorship

Related Conditions & MeSH terms

• Bronchial Cancer
• Carcinoma, Bronchogenic

Locations

Country	Name	City	State
France	Service de chirurgie thoracique - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retrospective histological study of tumor cell dissemination around the tumor		Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined